The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.
Identifieur interne : 000105 ( Main/Exploration ); précédent : 000104; suivant : 000106The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.
Auteurs : Nour K. Younis [Liban] ; Rana O. Zareef [Liban] ; Mohammad Ali N. Maktabi [Liban] ; Rami Mahfouz [Liban]Source :
- Genetic testing and molecular biomarkers [ 1945-0257 ] ; 2021.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), ARN viral (génétique), ARN viral (isolement et purification), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Antiviraux (usage thérapeutique), Charge mondiale de morbidité (statistiques et données numériques), Essais cliniques comme sujet (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Indice de gravité de la maladie (MeSH), Mutation (MeSH), Pandémies (prévention et contrôle), Pandémies (statistiques et données numériques), Utilisation hors indication (MeSH), Évolution moléculaire (MeSH).
- MESH :
- analogues et dérivés : AMP, Alanine.
- génétique : ARN viral.
- isolement et purification : ARN viral.
- prévention et contrôle : Pandémies.
- statistiques et données numériques : Charge mondiale de morbidité, Pandémies.
- usage thérapeutique : AMP, Alanine, Antiviraux, Hydroxychloroquine.
- Essais cliniques comme sujet, Humains, Indice de gravité de la maladie, Mutation, Utilisation hors indication, Évolution moléculaire.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antiviral Agents (therapeutic use), COVID-19 (diagnosis), COVID-19 (drug therapy), COVID-19 (epidemiology), COVID-19 (therapy), COVID-19 (virology), COVID-19 Testing (methods), COVID-19 Vaccines (therapeutic use), Clinical Trials as Topic (MeSH), Evolution, Molecular (MeSH), Global Burden of Disease (statistics & numerical data), Humans (MeSH), Hydroxychloroquine (therapeutic use), Mutation (MeSH), Off-Label Use (MeSH), Pandemics (prevention & control), Pandemics (statistics & numerical data), RNA, Viral (genetics), RNA, Viral (isolation & purification), SARS-CoV-2 (genetics), SARS-CoV-2 (immunology), SARS-CoV-2 (isolation & purification), SARS-CoV-2 (pathogenicity), Severity of Illness Index (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , genetics : RNA, Viral.
- chemical , isolation & purification : RNA, Viral.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antiviral Agents, COVID-19 Vaccines, Hydroxychloroquine.
- diagnosis : COVID-19.
- drug therapy : COVID-19.
- epidemiology : COVID-19.
- genetics : SARS-CoV-2.
- immunology : SARS-CoV-2.
- isolation & purification : SARS-CoV-2.
- methods : COVID-19 Testing.
- pathogenicity : SARS-CoV-2.
- prevention & control : Pandemics.
- statistics & numerical data : Global Burden of Disease, Pandemics.
- therapy : COVID-19.
- virology : COVID-19.
- Clinical Trials as Topic, Evolution, Molecular, Humans, Mutation, Off-Label Use, Severity of Illness Index.
Abstract
Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Until now, remdesivir is the only medication approved for the treatment of COVID-19 by the U.S. Food and Drug Administration (FDA); however, it is anticipated that several anti-SARS-CoV-2 monoclonal antibodies will gain soon approval. Other methods of treatment include supportive care directed toward treating the symptoms. Nevertheless, many studies have recently emerged, showing controversial preliminary results with the off-label medication hydroxychloroquine. Given that all results are still preliminary, including those seen by remdesivir, additional evidence and research are required to identify effective medications that are broadly effective and well tolerated. Importantly, two RNA-based vaccines have recently gained approval from Pfizer and Moderna, with many others still in clinical trials. This article reviews various aspects of COVID-19, including its epidemiology; its evolution and mutational spectrum; and its clinical dynamics, symptoms and complications, diagnosis, and treatment.
DOI: 10.1089/gtmb.2020.0227
PubMed: 33596144
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.</title><author><name sortKey="Younis, Nour K" sort="Younis, Nour K" uniqKey="Younis N" first="Nour K" last="Younis">Nour K. Younis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Zareef, Rana O" sort="Zareef, Rana O" uniqKey="Zareef R" first="Rana O" last="Zareef">Rana O. Zareef</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Maktabi, Mohammad Ali N" sort="Maktabi, Mohammad Ali N" uniqKey="Maktabi M" first="Mohammad Ali N" last="Maktabi">Mohammad Ali N. Maktabi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Mahfouz, Rami" sort="Mahfouz, Rami" uniqKey="Mahfouz R" first="Rami" last="Mahfouz">Rami Mahfouz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33596144</idno><idno type="pmid">33596144</idno><idno type="doi">10.1089/gtmb.2020.0227</idno><idno type="wicri:Area/Main/Corpus">000337</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000337</idno><idno type="wicri:Area/Main/Curation">000337</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000337</idno><idno type="wicri:Area/Main/Exploration">000337</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.</title><author><name sortKey="Younis, Nour K" sort="Younis, Nour K" uniqKey="Younis N" first="Nour K" last="Younis">Nour K. Younis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Zareef, Rana O" sort="Zareef, Rana O" uniqKey="Zareef R" first="Rana O" last="Zareef">Rana O. Zareef</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Maktabi, Mohammad Ali N" sort="Maktabi, Mohammad Ali N" uniqKey="Maktabi M" first="Mohammad Ali N" last="Maktabi">Mohammad Ali N. Maktabi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Mahfouz, Rami" sort="Mahfouz, Rami" uniqKey="Mahfouz R" first="Rami" last="Mahfouz">Rami Mahfouz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author></analytic><series><title level="j">Genetic testing and molecular biomarkers</title><idno type="eISSN">1945-0257</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (diagnosis)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>COVID-19 (therapy)</term><term>COVID-19 (virology)</term><term>COVID-19 Testing (methods)</term><term>COVID-19 Vaccines (therapeutic use)</term><term>Clinical Trials as Topic (MeSH)</term><term>Evolution, Molecular (MeSH)</term><term>Global Burden of Disease (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Mutation (MeSH)</term><term>Off-Label Use (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pandemics (statistics & numerical data)</term><term>RNA, Viral (genetics)</term><term>RNA, Viral (isolation & purification)</term><term>SARS-CoV-2 (genetics)</term><term>SARS-CoV-2 (immunology)</term><term>SARS-CoV-2 (isolation & purification)</term><term>SARS-CoV-2 (pathogenicity)</term><term>Severity of Illness Index (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term><term>AMP (usage thérapeutique)</term><term>ARN viral (génétique)</term><term>ARN viral (isolement et purification)</term><term>Alanine (analogues et dérivés)</term><term>Alanine (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Charge mondiale de morbidité (statistiques et données numériques)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Mutation (MeSH)</term><term>Pandémies (prévention et contrôle)</term><term>Pandémies (statistiques et données numériques)</term><term>Utilisation hors indication (MeSH)</term><term>Évolution moléculaire (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Antiviral Agents</term><term>COVID-19 Vaccines</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>ARN viral</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>COVID-19 Testing</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Pandémies</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Global Burden of Disease</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Charge mondiale de morbidité</term><term>Pandémies</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Antiviraux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Evolution, Molecular</term><term>Humans</term><term>Mutation</term><term>Off-Label Use</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais cliniques comme sujet</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Mutation</term><term>Utilisation hors indication</term><term>Évolution moléculaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Until now, remdesivir is the only medication approved for the treatment of COVID-19 by the U.S. Food and Drug Administration (FDA); however, it is anticipated that several anti-SARS-CoV-2 monoclonal antibodies will gain soon approval. Other methods of treatment include supportive care directed toward treating the symptoms. Nevertheless, many studies have recently emerged, showing controversial preliminary results with the off-label medication hydroxychloroquine. Given that all results are still preliminary, including those seen by remdesivir, additional evidence and research are required to identify effective medications that are broadly effective and well tolerated. Importantly, two RNA-based vaccines have recently gained approval from Pfizer and Moderna, with many others still in clinical trials. This article reviews various aspects of COVID-19, including its epidemiology; its evolution and mutational spectrum; and its clinical dynamics, symptoms and complications, diagnosis, and treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33596144</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1945-0257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Genetic testing and molecular biomarkers</Title><ISOAbbreviation>Genet Test Mol Biomarkers</ISOAbbreviation></Journal><ArticleTitle>The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.</ArticleTitle><Pagination><MedlinePgn>85-101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/gtmb.2020.0227</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Until now, remdesivir is the only medication approved for the treatment of COVID-19 by the U.S. Food and Drug Administration (FDA); however, it is anticipated that several anti-SARS-CoV-2 monoclonal antibodies will gain soon approval. Other methods of treatment include supportive care directed toward treating the symptoms. Nevertheless, many studies have recently emerged, showing controversial preliminary results with the off-label medication hydroxychloroquine. Given that all results are still preliminary, including those seen by remdesivir, additional evidence and research are required to identify effective medications that are broadly effective and well tolerated. Importantly, two RNA-based vaccines have recently gained approval from Pfizer and Moderna, with many others still in clinical trials. This article reviews various aspects of COVID-19, including its epidemiology; its evolution and mutational spectrum; and its clinical dynamics, symptoms and complications, diagnosis, and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Younis</LastName><ForeName>Nour K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zareef</LastName><ForeName>Rana O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maktabi</LastName><ForeName>Mohammad Ali N</ForeName><Initials>MAN</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahfouz</LastName><ForeName>Rami</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genet Test Mol Biomarkers</MedlineTA><NlmUniqueID>101494210</NlmUniqueID><ISSNLinking>1945-0257</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071219" MajorTopicYN="N">Global Burden of Disease</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>17</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33596144</ArticleId><ArticleId IdType="doi">10.1089/gtmb.2020.0227</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Liban</li></country></list><tree><country name="Liban"><noRegion><name sortKey="Younis, Nour K" sort="Younis, Nour K" uniqKey="Younis N" first="Nour K" last="Younis">Nour K. Younis</name></noRegion><name sortKey="Mahfouz, Rami" sort="Mahfouz, Rami" uniqKey="Mahfouz R" first="Rami" last="Mahfouz">Rami Mahfouz</name><name sortKey="Maktabi, Mohammad Ali N" sort="Maktabi, Mohammad Ali N" uniqKey="Maktabi M" first="Mohammad Ali N" last="Maktabi">Mohammad Ali N. Maktabi</name><name sortKey="Zareef, Rana O" sort="Zareef, Rana O" uniqKey="Zareef R" first="Rana O" last="Zareef">Rana O. Zareef</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000105 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000105 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33596144
|texte= The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33596144" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |